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Copy number variants (CNVs) have been strongly implicated in the genetic etiology of schizophrenia (SCZ). However, genome-
wide investigation of the contribution of CNV to risk has been hampered by limited sample sizes. We sought to address this 
obstacle by applying a centralized analysis pipeline to a SCZ cohort of 21,094 cases and 20,227 controls. A global enrichment  
of CNV burden was observed in cases (odds ratio (OR) = 1.11, P = 5.7 × 10−15), which persisted after excluding loci implicated  
in previous studies (OR = 1.07, P = 1.7 × 10−6). CNV burden was enriched for genes associated with synaptic function  
(OR = 1.68, P = 2.8 × 10−11) and neurobehavioral phenotypes in mouse (OR = 1.18, P = 7.3 × 10−5). Genome-wide significant 
evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 
16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate susceptibility and protective loci, which 
consisted predominantly of CNVs mediated by nonallelic homologous recombination.
RESULTS
Data processing and meta-analytic methods
Raw intensity data were obtained from 57,577 subjects and 43 separate 
data sets (Supplementary Table 2). After CNV calling and quality 
control (QC), 41,321 subjects were retained for analysis. We developed 
a centralized pipeline for systematic calling of CNVs for Affymetrix 
and Illumina platforms (Online Methods and Supplementary Fig. 1). 
The pipeline included multiple CNV callers run in parallel. Data from 
Illumina platforms were processed using PennCNV15 and iPattern16. 
Data from Affymetrix platforms were analyzed using PennCNV and 
Birdsuite17.Two additional methods, iPattern and C-score18, were 
applied to data from the Affymetrix 6.0 platform. To ensure proper 
normalization of the X chromosome, male and female subjects were 
normalized separately. The CNV calls from each program were con-
verted to a standardized format, and a consensus call set was constructed 
by merging CNV outputs at the sample level. Only CNV segments that 
were detected by all algorithms were retained. We performed QC at 
the platform level to exclude samples with poor probe intensity and/or 
an excessive CNV load (number and length). A final set of rare, high-
quality CNVs was defined as those >20 kb in length, encompassing at 
least 10 probes and <1% minor allele frequency (MAF).
Genetic associations were investigated by case-control tests of CNV 
burden at four levels: (i) genome-wide (ii) pathways, (iii) genes and 
(iv) CNV breakpoints. Analyses controlled for SNP-derived princi-
pal components, sex, genotyping platform and data quality metrics. 
Multiple-testing thresholds for genome-wide significance were esti-
mated from family-wise error rates drawn from permutation.
Genome-wide analysis of CNV burden
An elevated burden of rare CNVs among SCZ cases has been well 
established2. We applied our meta-analytic framework to measure 
Contribution of copy number variants to schizophrenia 
from a genome-wide study of 41,321 subjects
Studies of genomic copy number variation (CNV) have established a 
role for rare genetic variants in the etiology of SCZ1. There are three 
lines of evidence that CNVs contribute to risk for SCZ: genome-wide 
enrichment of rare deletions and duplications in SCZ cases relative to 
controls2,3, a higher rate of de novo CNVs in cases relative to controls4–6 
and association evidence implicating a small number of specific loci 
(Supplementary Table 1). All CNVs that have been implicated in SCZ 
are rare in the population but confer significant risk (ORs 2–60).
To date, CNVs associated with SCZ have largely emerged from 
mergers of summary data for specific candidate loci7–9; yet even the 
largest genome-wide scans (sample sizes typically <10,000) remain 
underpowered to robustly confirm genetic association for the major-
ity of pathogenic CNVs reported so far, particularly for those with low 
frequencies (<0.5% in cases) or intermediate effect sizes (ORs 2–10). 
It is important to address the low power of CNV studies with larger 
samples, given that this type of mutation has already proven useful for 
highlighting some aspects of SCZ-related biology6,10–13.
The limited statistical power provided by small samples is a sub-
stantial obstacle in studies of rare and common genetic variation. In 
response, global collaborations have been formed to attain large sample 
sizes, as exemplified by a genome wide association study (GWAS) of SCZ 
by the Psychiatric Genomics Consortium (PGC) by the Schizophrenia 
Working Group of the Psychiatric Genomics Consortium (PGC), 
which identified 108 independent SCZ-associated loci14. Recognizing 
the need for similarly large samples in studies of CNVs for psychiatric 
disorders, we formed the PGC CNV Analysis Group. Our goal was to 
enable large-scale analysis of CNVs in psychiatry using centralized and 
uniform methodologies for CNV calling, quality control and statistical 
analysis. Here we report the largest genome-wide analysis of CNVs 
for any psychiatric disorder to date, using data sets assembled by the 
Schizophrenia Working Group of the PGC.
A full list of authors and affiliations appears at the end of the paper.
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the consistency of overall CNV burden across genotyping platforms 
and investigate whether a measurable CNV burden persists outside 
of previously implicated CNV regions. Consistent with previous 
estimates, the overall CNV burden was significantly greater among 
SCZ cases when measured as total distance (kb) covered (OR = 1.12, 
P = 5.7 × 10−15), genes affected (OR = 1.21, P = 6.6 × 10−21) or CNV 
number (OR = 1.03, P = 1 × 10−3). The burden signal above was driven 
by CNVs located within genes. Focusing therefore on the number of 
genes affected by CNV, which was the burden metric with the strong-
est signal of enrichment in our study, the effect size was consistent 
across all genotyping platforms (Fig. 1a). When we split by CNV type, 
the effect size for copy number losses (OR = 1.40, P = 4 × 10−16) was 
greater than for gains (OR = 1.12, P = 2 × 10−7) (Supplementary Figs. 2 
and 3). Partitioning by CNV frequency (based on 50% reciprocal 
overlap with the full call set; Online Methods), CNV burden was 
enriched among cases across a range of frequencies, up to counts of 80 
(MAF = 0.4%) in the combined sample (Fig. 1b). CNV burden results 
for individual cohorts are provided in Supplementary Figure 4. 
We observed no enrichment in CNV burden when considering only 
variants that did not overlap exons (Supplementary Fig. 5).
A primary question in this study is how novel loci contribute to 
excess CNV burden in cases. After removing nine previously implicated 
CNV loci (where reported P values exceed our designated multiple test-
ing threshold) (Supplementary Table 1), excess CNV burden in SCZ 
remained significantly enriched (genes affected OR = 1.11, P = 1.3 × 
10−7) (Fig. 1b). CNV burden also remained significantly enriched 
after removal of all reported loci from Supplementary Table 1, 
but the effect size was greatly reduced (OR = 1.08) compared to the 
enrichment overall (OR = 1.21). When we partitioned CNV burden by 
frequency, we found that much of the previously unexplained signal 
was restricted to ultra-rare events (i.e., MAF < 0.1%) (Fig. 1b).
Gene set (pathway) burden
We assessed whether CNV burden was concentrated within defined 
sets of genes involved in neurodevelopment or neurological function. 
We evaluated a total of 36 gene sets (Supplementary Table 3), includ-
ing gene sets representing neuronal function, synaptic components 
and neurological and neurodevelopmental phenotypes in human 
(19 sets); gene sets based on brain expression patterns (7 sets) and 
human orthologs of mouse genes whose disruption causes pheno-
typic abnormalities, including neurobehavioral and nervous system 
abnormality (10 sets). Genes not expressed in brain (1 set) or associ-
ated with abnormal phenotypes in mouse organ systems unrelated to 
brain (7 sets) were included as negative controls. We mapped CNVs 
to genes if they overlapped by at least one exonic base pair.
Gene set burden was measured using a logistic regression deviance 
test6. In addition to using the same covariates included in genome-
wide burden analysis, we controlled for the total number of genes 
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Figure 1 CNV burden. (a) Forest plot of CNV burden (measured as 
genes affected by CNV), partitioned by genotyping platform, with the 
full Psychiatric Genomics Consortium (PGC) sample at the bottom. CNV 
burden is calculated by combining CNV gains and losses. ‘Genes’ denotes 
the mean number of genes affected by a CNV in controls. Burden tests 
use a logistic regression model predicting SCZ case-control status by CNV 
burden along with covariates (Online Methods). The OR is the exponential 
of the logistic regression coefficient, and OR > 1 predicts increased SCZ 
risk. A500, Affymetrix 500; I300, Illumina 300K; I600, Illumina 610K 
and Illumina 660W; A5.0, Affymetrix 5.0; A6.0, Affymetrix 6.0; Omni, 
OmniExpress and OmniExpress plus Exome. (b) CNV burden partitioned 
by CNV frequency. For autosomal CNVs, a CNV count of 41 in the sample 
corresponds to frequency of 0.1% in the full PGC sample. Using the 
same model as above, each CNV was placed into a single CNV frequency 
category on the basis of a 50% reciprocal overlap with other CNVs. CNV 
gene burden with inclusion of all CNVs is shown in green, and burden 
excluding previously implicated CNV loci is shown in blue.
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Figure 2 Gene set burden. (a–d) Gene set burden test results for rare 
losses (a,c) and gains (b,d) in gene sets for neuronal function, synaptic 
components, neurological and neurodevelopmental phenotypes in human 
(a,b) and gene sets for human homologs of mouse genes implicated 
in abnormal phenotypes (organized by organ systems) (c,d), sorted by 
−log10 of the logistic regression deviance test P value multiplied by the 
beta coefficient sign, obtained for rare losses when including known loci. 
Asterisk denotes gene sets passing the 10% BH-FDR threshold. Gene sets 
representing brain expression patterns are not shown, because only a few 
were significant (losses, 1; gains, 3).
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per subject spanned by rare CNVs to account for signal that merely 
reflects the global enrichment of CNV burden in cases19. Multiple-
testing correction (Benjamini–Hochberg false discovery rate (BH-
FDR)) was performed separately for each gene set group and CNV 
type (gains, losses). After multiple test correction (BH-FDR ≤ 10%) 
15 gene sets were enriched for rare loss burden in cases and 4 for rare 
gains in cases, none of which were negative control sets (Fig. 2).
Of the 15 sets significant for losses, the majority consisted of syn-
aptic or other neuronal components (9 sets); in particular, GO terms 
synapse and activity-regulated cytoskeleton-associated protein (ARC) 
complex rank first on the basis of statistical significance and effect 
size, respectively (Fig. 2a). Losses in cases were also significantly 
enriched for genes involved in nervous system or behavioral phe-
notypes in mouse but not for gene sets related to other organ system 
phenotypes (Fig. 2c). To account for dependency between synaptic 
and neuronal gene sets, we retested loss burden following a step-
down logistic regression approach, ranking gene sets on the basis of 
significance or effect size (Supplementary Table 4). Only GO terms 
synapse and ARC complex were significant in at least one of the two 
step-down analyses, suggesting that burden enrichment in the other 
neuronal categories is captured mostly by the overlap with synaptic 
genes. Following the same approach, the mouse neurological and neu-
robehavioral phenotype set remained nominally significant (P = 0.01), 
suggesting that a portion of this signal was independent of the syn-
aptic gene set. Pathway enrichment was less pronounced for dupli-
cations, consistent with the smaller burden effects for this class of 
CNV. Among synaptic or other neuronal components, duplication 
burden was significantly enriched only for NMDA receptor complex 
(Fig. 2b); none of the mouse phenotype sets passed the significance 
threshold for duplications (Fig. 2d).
Given that synaptic gene sets were robustly enriched for deletions 
in cases and showed an appreciable contribution from loci that have 
not been strongly associated with SCZ previously, we further investi-
gated pathway-level interactions of these sets. A protein-interaction 
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Figure 3 Encoded-protein interaction network for synaptic genes. Synaptic and ARC-complex genes intersected by a rare loss in at least four case or 
control subjects and with genic burden BH-FDR 25% (red discs) were used to query GeneMANIA36 and retrieve additional encoded-protein interaction 
neighbors, resulting in a network of 136 synaptic genes. Genes are depicted as disks; disk centers are colored on the basis of rare loss frequency being 
prevalent in cases (Freq.SZ) or controls (Freq.CT); disk borders are colored to mark gene implication in human dominant or X-linked neurological or 
neurodevelopmental phenotype, de novo mutation (DeN) reported by Fromer et al.28, split between loss-of-function (LOF) (frameshift, stop-gain, core 
splice site) and missense or amino acid insertion or deletion (aa in/del); implication in mouse neurobehavioral abnormality. Genes encoding presynaptic 
adhesion molecules (NRXN1, NRXN3), postsynaptic scaffolds (DLG1, DLG2, DLGAP1, SHANK1, SHANK2) and glutamatergic ionotropic receptors 
(GRID1, GRID2, GRIN1, GRIA4) constitute a highly connected subnetwork with more losses in cases than in controls.
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network was seeded using the synaptic- and ARC complex–associated 
genes that were intersected by rare deletions in this study (Fig. 3). 
A graph of the network highlights multiple subnetworks of synap-
tic proteins including presynaptic adhesion molecules (NRXN1, 
NRXN3), postsynaptic scaffolding proteins (DLG1, DLG2, DLGAP1, 
SHANK1, SHANK2), glutamatergic ionotropic receptors (GRID1, 
GRID2, GRIN1, GRIA4), and complexes such as dystrophin and its 
synaptic interacting proteins (DMD, DTNB, SNTB1, UTRN). A sub-
sequent test of the dystrophin glycoprotein complex (DGC) showed 
that deletion burden of the synaptic DGC proteins (intersection of GO 
terms DGC and synapse was enriched in cases (deviance test P = 0.05), 
but deletion burden of the full DGC was not significant (P = 0.69).
Gene–CNV association
To define specific loci that confer risk for SCZ, we tested CNV asso-
ciation at the level of individual genes, using logistic regression devi-
ance test and the same covariates included in genome-wide burden 
analysis. To correctly account for large CNVs that affect multiple 
genes, we aggregated adjacent genes into a single locus if their copy 
number was highly correlated across subjects (more than 50% subject 
overlap). CNVs were mapped to genes if they overlapped one or more 
exons. The criterion for genome-wide significance was a family-wise 
error rate (FWER) < 0.05. The criterion for suggestive evidence was 
a BH-FDR < 0.05.
Of 18 independent CNV loci with gene-based BH-FDR < 0.05, 
two were excluded on the basis of CNV calling accuracy or evidence 
of a batch effect (Supplementary Note). The 16 loci that remained 
after these additional QC steps, comprising 17 separate association 
signals, are listed in Table 1. P values for this summary table were 
obtained by re-running our statistical model across the entire region 
(Supplementary Note). These 16 loci represent a set of novel (n = 6), 
previously reported (n = 4) and previously implicated (n = 7) regions, 
with 22q11.21 comprising two separate association signals at the same 
locus. Manhattan plots of the gene association for losses and gains 
are shown in Figure 4. A permutation-based FDR yielded similar 
estimates to BH-FDR.
Eight loci attain genome-wide significance, including copy number 
losses at 1q21.1, 2p16.3 (NRXN1), 3q29, 15q13.3, 16p11.2 (distal) 
and 22q11.2 along with gains at 7q11.23 and 16p11.2 (proximal). An 
additional eight loci met criteria for suggestive association, including 
six that have not been reported previously in association with SCZ. 
On the basis of our estimation of FDR values (BH and permutations), 
we expect to observe <2 associations meeting suggestive criteria by 
chance. To further evaluate the six candidate loci identified here, 
we performed experimental validation of CNV calls in a subset of 
samples by digital droplet PCR (ddPCR; Online Methods). Validation 
rates of 100% were obtained for gains of DMRT1, MAGEA11 and 
distal Xq28, losses of VPS13B and gains and losses of ZNF92 
(Supplementary Table 5). We obtained a low validation rate at one 
locus, ZMYM5 (64%) and therefore do not consider the association 
at this locus convincing.
Breakpoint-level CNV association
With our sample size and uniform CNV calling pipeline, many indi-
vidual CNV loci can be tested with adequate power at the CNV break-
point level (i.e., the SNP probe defining the start and end of the CNV 
segment), potentially facilitating discovery at a finer resolution than 
locus-wide tests. Tests for association were performed at each CNV 
breakpoint using the residuals of case-control status after controlling 
for analysis covariates, with significance determined through per-
mutation. Results for losses and gains are shown in Supplementary ta
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Figure 6. Four independent CNV loci surpass genome-wide sig-
nificance, all of which were also identified in the gene-based test, 
including the 15q13.2–13.3 and 22q11.21 deletions, 16p11.2 duplica-
tion, and 1q21.1 deletion and duplication. While these loci represent 
fewer than half of the loci previously implicated in SCZ, we do find 
support for all loci where the association originally reported meets 
the criteria for genome-wide correction in this study. We examined 
association among all previously reported loci showing association 
to SCZ, including 18 CNV losses and 25 CNV gains (Supplementary 
Table 6); 8 loci have BH-FDR q-value < 0.05, 13 loci have BH-FDR 
q-value < 0.1, and 25 of the 42 loci were associated with SCZ at an 
uncorrected P < 0.05.
Associations at some loci become better delineated through break-
point-level analysis. For instance, NRXN1 at 2p16.3 is a CNV hot 
spot, and exonic deletions of this gene are significantly enriched in 
SCZ9,20. In this large sample, we observe a high density of ‘nonre-
current’ deletion breakpoints in cases and controls. A snapshot of 
the breakpoint-associationassociation results from the PGC CNV 
browser (Online Methods) shows a sawtooth pattern of association. 
Predominant peaks correspond to exons and transcriptional start sites 
of NRXN1 isoforms (Fig. 5). This example highlights how, with high 
diversity of alleles at a single locus, the association peak may become 
more refined and, in some cases, converge toward individual func-
tional elements. Similarly, visualization of the previously reported 
SCZ risk loci on 16p13.2 and 8q11.23 showed a high density of dupli-
cation breakpoints, which better delineate genes in these regions. It 
is important, however, to note that CNV breakpoints in the current 
study are estimated from genotyped SNPs around the true breakpoint 
and that these breakpoint estimates are limited by the resolution of 
the genotyping platform and therefore subject to error.
Novel risk alleles are predominantly NAHR-mediated CNVs
Many CNV loci that have been strongly implicated in human disease 
are hot spots for nonallelic homologous recombination (NAHR), a 
process that in most cases is mediated by flanking segmental dupli-
cations21. We defined a CNV as NAHR when both the start and end 
breakpoints were located within a segmental duplication. Consistent 
with the importance of NAHR in generating CNV risk alleles for 
SCZ, most of the loci in Table 1 are flanked by segmental duplica-
tions. Moreover, after excluding loci implicated in previous studies, 
the remaining loci with FDR < 0.05 in the gene-base burden test 
were NAHR enriched (6.03-fold, P = 0.008; Supplementary Fig. 7) 
when compared to a null distribution determined by randomizing the 
genomic positions of associated genes (Supplementary Note). These 
findings suggest that the novel SCZ-associated CNVs are similar to 
known pathogenic CNVs in that they tend to occur in regions prone 
to high rates of recurrent mutation.
DISCUSSION
The present study of the PGC SCZ CNV data set includes the major-
ity of all microarray data that have been generated in genetic stud-
ies of SCZ to date. In this we find definitive evidence for eight loci, 
surpassing strict genome-wide multiple testing correction. We also 
find evidence for a contribution of novel CNVs conferring either 
risk or protection to SCZ, with an FDR < 0.05. The complete results, 
including CNV calls and statistical evidence at the gene or breakpoint 
level, can be viewed using the PGC CNV browser (Online Methods). 
Our data suggest that the undiscovered novel risk loci that can be 
detected with current genotyping platforms lie at the ultra-rare end 
of the frequency spectrum and still larger samples will be needed to 
identify them at convincing levels of statistical evidence.
Collectively, the eight SCZ risk loci that surpass genome-wide 
significance are carried by a small fraction (1.4%) of SCZ cases in 
the PGC sample. We estimate 0.85% of the variance in SCZ liabil-
ity is explained by carrying a CNV risk allele within these loci 
(Supplementary Note). As a comparison, 3.4% of the variance in 
SCZ liability is explained by the 108 genome-wide significant loci 
identified in the companion PGC GWAS analysis. Combined, the 
CNV and SNP loci that have been identified to date explain a small 
proportion (<5%) of heritability. The large data set here provides an 
opportunity to evaluate the strength of evidence for a variety of loci 
where an association with SCZ has been reported previously. Of 44 
published findings from the recent literature, we find evidence for 
eight loci (at FDR 5%) and nominal support for an additional 17 loci 
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(uncorrected P < 0.05; Supplementary Table 6). Thus, nearly half 
of the existing candidate loci retain some support in our combined 
analysis. However, we also find a lack of evidence for many of the 
previously identified loci, underscoring the value of meta-analytic 
efforts to assess the validity of such reports. A lack of strong evidence 
in this data set (which includes samples that overlap with many of 
the previous studies) may in some cases simply reflect that statistical 
power is limited for very rare variants, even in large samples. However, 
it is likely that some of the earlier findings represent chance asso-
ciations; indeed, the loci that are not supported by our data consist 
largely of loci for which the original statistical evidence was weak 
(Supplementary Table 6). Thus, our results help to refine the list of 
promising candidate CNVs. Continued efforts to evaluate the grow-
ing number of candidate variants has considerable value for directing 
future research efforts focused on specific loci.
The novel candidate loci meeting suggestive criteria in this study 
include two regions on chromosome X. It has been hypothesized 
that sex-linked loci contribute to SCZ, originally on the basis of the 
observation of an increased rate of sex chromosome aneuploidy in 
cases22. X-linked loci were not detected in previous CNV studies of 
SCZ, because none evaluated variants on the sex chromosomes. In 
the current study, accurate calls were obtained by controlling for sex 
chromosome ploidy in the normalization and variant calling methods. 
Notably, duplications of distal Xq28 (regional P = 3.6 × 10−4, OR = 8.9) 
(Table 1 and Supplementary Fig. 8) appear to confer risk for SCZ 
in both males and females, and the effect size was greatest in males 
(P = 0.01, OR = ). Similar patterns consistent with dominant 
X-linked effects were observed at other loci (Supplementary Table 7). 
Duplications of distal Xq28 have been reported in association with 
developmental delay in both sexes23,24. Notably, of 26 subjects that 
have been described clinically, nearly half (12/26) have behavioral 
or psychiatric conditions. Of the five reciprocal deletions that were 
detected in this study, none were observed in males, consistent with 
hemizygous loss of distal Xq28 being associated with recessive embry-
onic lethality in males24. Thus, mounting evidence indicates that 
increased copy number of distal Xq28 is associated with psychiatric 
illness. These results also provide a further demonstration that CNV 
risk factors in SCZ overlap with loci that contribute to pediatric devel-
opmental disorders1,25.
We observed multiple ‘protective’ CNVs that showed a sugges-
tive enrichment in controls, including duplications of 22q11.2 and 
MAGEA11 along with deletions and duplications of ZNF92. No 
protective effects were significant after genome-wide correction. 
Moreover, a rare CNV that confers reduced risk for SCZ may not 
confer a general protection from neurodevelopmental disorders. For 
example, microduplications of 22q11.2 appear to confer protection 
from SCZ26; however, such duplications have been shown to increase 
risk for developmental delay and a variety of congenital anomalies in 
pediatric clinical populations27. It is probable that some of the undis-
covered rare alleles affecting risk for SCZ confer protection, but larger 
sample sizes are needed to determine this unequivocally. If it is true 
that a proportion of CNVs observed in our control sample represent 
rare protective alleles, then the heritability of SCZ explained by CNVs 
may not be fully accounted for by the excess CNV burden in cases.
Our results provide strong evidence that deletions in SCZ are 
enriched within a highly connected network of synaptic proteins, 
consistent with previous studies2,6,10,28. The large CNV data set here 
allows a more detailed view of the synaptic network and highlights 
subsets of genes accounting for the excess deletion burden in SCZ, 
including those affecting synaptic cell adhesion and scaffolding pro-
teins, glutamatergic ionotropic receptors and protein complexes such 
as the ARC complex and DGC. Modest CNV evidence implicating 
dystrophin (DMD) and its binding partners is notable, given that the 
involvement of certain components of the DGC have been postu-
lated29,30 and disputed31 previously. Larger studies of CNV are needed 
to define a role for this and other synaptic subnetworks in SCZ.
Our current study is well powered to detect CNVs of large effect 
that occur in >0.1% of cases but is underpowered to detect association 
to variants with modest effect sizes or to ultra-rare variants regardless 
of effect size. Furthermore, this study did not assess the contribution 
of common CNVs to SCZ, one instance of which we know: a recent 
study demonstrated that the causal variants underlying the strongest 
common variant association in SCZ include duplications of the gene 
encoding complement factor 4A32. Last, we recognize that a major-
ity of structural variants are not detectable with current genotyping 
platforms33. New technologies for whole-genome sequencing will 
ultimately provide an assessment of the contribution of a wider array 
of rare variants, including balanced rearrangements, small CNVs34 
and short tandem repeats35.
Large-scale collaborations in psychiatric genetics have greatly 
advanced discovery through genome-wide association studies. Here 
we have extended this framework to rare CNVs. Our knowledge of 
the contribution from lower-frequency variants gives us confidence 
that the application of this framework to large newly acquired data 
sets has the potential to further the discovery of loci and identification 
of the relevant genes and functional elements.
METHODS
Methods, including statements of data availability and any associated 
accession codes and references, are available in the online version of 
the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Overview. We assembled a CNV analysis group with the goal of leveraging 
the extensive expertise within the Psychiatric Genomics Consortium (PGC) 
to develop a fully automated centralized pipeline for consistent and systematic 
calling of CNVs for both Affymetrix and Illumina platforms. An overview 
of the analysis pipeline is shown in Supplementary Figure 1. After an ini-
tial data formatting step, we constructed batches of samples for processing 
using PennCNV, iPattern, C-score (GADA and HMMSeg) and Birdsuite for 
Affymetrix 6.0. For Affymetrix 5.0 data we used Birdsuite and PennCNV; 
for Affymetrix 500 we used PennCNV and C-score; and for all Illumina arrays 
we used PennCNV and iPattern. We then constructed a consensus CNV call 
data set by merging data at the sample level and further filtered calls to make 
a final data set (Supplementary Table 2). Prior to any filtering, we processed 
raw genotype calls for a total of 57,577 individuals, including 28,684 SCZ cases 
and 28,893 controls.
Study sample. A complete list of data sets included in the current study can be 
found in Supplementary Table 2. A more detailed description of the original 
studies can be found in a previous publication1.
CNV Analysis pipeline architecture and sample processing. All aspects 
of the CNV analysis pipeline were built on the Genetic Cluster Computer 
(GCC) (see below).
Input acceptance and preprocessing. For Affymetrix we used CEL files (all 
converted to the same format) as input, whereas for Illumina we required 
Genome or Beadstudio exported TXT files with the following values: sam-
ple ID, SNP name, chr, position, allele1 – forward, allele2 – forward, X, Y, 
B allele freq and log R ratio. Samples were then partitioned into ‘batches’ to 
be run through each pipeline. For Affymetrix samples, we created analysis 
batches on the basis of the plate ID (if available) or genotyping date. Each 
batch had approximately 200 samples. Each batch included at least 50 sub-
jects of each sex. Affymetrix Power Tools (APT - apt-copynumber-workflow) 
was then used to calculate summary statistics about chips analyzed. Gender 
mismatches were identified and excluded as were experiments with MAPD > 
0.4. For Illumina data, we first determined the genome build and converted 
to hg18 if necessary and created analysis batches on the basis of the plate ID 
or genotyping date.
Composite pipeline. The composite pipeline comprises CNV callers 
PennCNV2, iPattern3, Birdsuite4 and C-Score5 organized into component pipe-
lines. We used all four callers for Affymetrix 6.0 data, and we used PennCNV 
and C-Score for Affymetrix 500. Probe annotation files were preprocessed 
for each platform. Once the array design files and probe annotation files were 
preprocessed, each individual pipeline component pipeline was run in two 
steps: (i) processing the intensity data by the core pipeline process to produce 
CNV calls and (ii) parsing the specific output format of the core pipeline and 
converting the calls to a standard form designed to capture confidence scores, 
copy number states and other information computed by each pipeline.
Merging of CNV data and QC filtering is described in detail in the 
Supplementary Note. Briefly, for each subject, CNV calls were made using 
multiple algorithms. Only CNV calls that were made using multiple algo-
rithms were included in the call set. Sample level QC filtering was performed 
by removing arrays with excessive probe variance or GC bias and removal 
of samples with mismatches in gender or ethnicity or chromosomal aneu-
ploidies. The final filtered CNV data set was annotated with Refseq genes 
(transcriptions and exons). After this stage of QC, we had a total of 52,511 
individuals, with 27,034 SCZ cases and 25,448 controls. To make our final 
data set of rare CNVs for all subsequent analysis we filtered out variants that 
were present at ≥1% (50% reciprocal overlap) frequency in cases and controls 
combined. We included in the call set CNVs that were ≥20 kb and ≥10 probes 
in length and overlapped <50% with regions tagged as copy number polymor-
phic on any other platform.
To minimize the impact of technical artifacts and potential confounds on 
CNV association results, we removed from the data set individuals that did not 
pass QC filtering from the companion PGC GWAS study of schizophrenia1 
as well as well as case or control samples that could not be matched by array 
platform or reconciled by using a common set of probes.
Statistics. Regression of potential confounds on case-control ascertainment. The 
PGC cohorts are a combination of many data sets drawn from the US and 
Europe, and it is important to ensure that any bias in sample ascertainment 
does not drive spurious association to SCZ. In order to ensure the robustness 
of the analysis, burden and gene set analyses included potential confounding 
variables as covariates in a logistic regression framework. Owing to the number 
of tests run at breakpoint-level association, we employed a step-wise logistic 
regression approach to allow for the inclusion of covariates in our case-control 
association, which we term the SCZ residual phenotype.
Covariates included sex, genotyping platform and ancestry principal com-
ponents derived from SNP genotypes on the same samples in a previous study1. 
Control for population stratification is described in the Supplementary Note. 
We were unable to control for data set or genotyping batch, as a subset of the 
contributing data sets are fully confounded with case-control status. Only 
principal components that showed a significant association to small CNV 
burden were used (small CNV being defined as autosomal CNV burden with 
CNV < 100 kb). Among the top 20 principal components, only the first, 
second, third, fourth and eighth principal components showed association 
with small CNV burden (with P < 0.01 used as the significance cutoff).
Last, in order to control for case-control differences in CNV ascertainment 
due to data quality we sought to identify data quality metrics that were con-
founded with case status. Affymetrix (MAPD and waviness-sd) and Illumina 
(LRRSD, BAFSD, GCWF) QC metrics were re-examined across studies to 
assess whether any additional outliers were present. Three outliers were 
removed, as their mean B allele (or minor allele) frequency deviated signifi-
cantly from 0.5. Many CNV metrics are autocorrelated, as they measure similar 
patterns of variation in the probe intensity. Thus, we focused on the primary 
measure of probe variance—MAPD and LRRSD. Among Affymetrix 6.0 data 
sets, MAPD did not differ between in cases and controls (t = 1.14, P = 0.25). 
However, among non-Affymetrix 6.0 data sets, LRRSD showed significant 
differences between cases and controls (t = −35.3, P < 2 ×10−16), with con-
trols having a higher standardized mean LRRSD (0.227) than cases (−0.199). 
Thus, to control for any spurious associations driven by CNV calling qual-
ity, we included MAPD (for Affymetrix platforms) or LRRSD (for Illumina 
platforms) as covariates in downstream analysis, which we designate as our 
CNV metric covariate for each individual. Prior to inclusion in the combined 
data set, the CNV metric variable was normalized within each respective 
genotyping platform.
To calculate the SCZ residual phenotype, we first fit a logistic regres-
sion model of covariates to affection status, and then extracted the Pearson 
residual values for use in a quantitative association design for downstream 
analyses. Residual phenotype values in cases are all above 0, and controls are 
below 0 and are graphed against overall kilobase burden in Supplementary 
Figure 9. We removed three individuals with an SCZ residual phenotype >3 
(or −3 in controls). After the post-processing round of QC, we retained a 
data set with a total of 41,321 individuals comprising 21,094 SCZ cases and 
20,227 controls.
CNV burden analysis. We analyzed the overall CNV burden in a variety of 
ways to discern which general properties of CNV are contributing to SCZ 
risk. Overall individual CNV burden was measured in three distinct ways: 
(i) kilobase burden of CNVs, (ii) number of genes affected by CNVs and (iii) 
number of CNVs. Genes were counted only if the CNV overlapped a coding 
exon. We also partitioned our analyses by CNV type, size and frequency. CNV 
type is defined as copy number losses (or deletions), copy number gains (or 
duplications) or both copy number losses and gains. To assign a specific allele 
frequency to a CNV, we used the–cnv-freq-method2 command in PLINK, 
whereby the frequency is determined as the total number of CNVs overlapping 
the target CNV segment by at least 50%. This method differs from other meth-
ods that assign CNV frequencies by genomic region, whereby a single CNV 
spanning multiple regions may be included in multiple frequency categories.
For Figure 1, and Supplementary Figures 2 and 3, we partitioned CNV 
burden by genotyping platform. Owing to the small sample size of the Omni 
2.5 array (28 cases and 10 controls), they were excluded from presentation in 
the figures but are included in all burden analyses with the total PGC sample. 
Using a logistic regression framework with the inclusion of covariates detailed 
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above, we predicted SCZ status using CNV burden as an independent predic-
tor variable, thus enabling an accurate estimate of the contribution of CNV 
burden. In addition, to determine the proportion of CNV burden risk that is 
attributable to loci that have not been implicated in previous studies of SCZ, 
we ran all burden analyses after removing CNVs that overlapped previously 
implicated CNV boundaries by more than 10%.
CNV breakpoint-level association. Association was tested at each respective 
CNV breakpoint. Three categories of CNV were tested: deletions, duplications 
and deletions and duplications combined. All analyses were run in PLINK6.
We ran breakpoint-level association using the SCZ residual phenotype as 
a quantitative variable, with significance determined through permutation 
of phenotype residual labels. An additional z-scoring correction, explained 
below, was used to control for any extreme values in the SCZ residual 
phenotype and efficiently estimate two-sided empirical P values for 
highly significant loci. To ensure against the potential loss of power from 
the inclusion of covariates, we also ran a single degree of freedom Cochran-
Mantel-Haenzel (CMH) test stratified by genotyping platform, with a 2 
(CNV carrier status) × 2 (phenotype status) × N (genotyping platform) con-
tingency matrix. Although the CMH test does not account for more subtle 
biases that could drive false positive signals, it is robust to signals driven by 
a single platform and allows for each CNV carrier to be treated equally. Loci 
that surpassed genome-wide correction in either test were followed up 
for further evaluation.
z-score recalibration of empirical testing. Breakpoint-level association 
P values from the SCZ residual phenotype were initially obtained by perform-
ing 1 million permutations at each CNV position, wherein each permutation 
shuffles the SCZ residual phenotype among all samples and retains the SCZ 
residual mean for CNV carriers and noncarriers. For extremely rare CNVs, 
however, CNV carriers at the extreme ends of the SCZ residual phenotype 
can produce highly significant P values. Although we understand that such 
rare events are unable to surpass strict genome-wide correction, we wanted 
to retain all tests to help delineate the potential fine-scale architecture within 
a single region of association. To properly account for the increased variance 
when only a few individuals are tested, we applied an empirical z-score cor-
rection to the CNV carrier mean. In order to get an empirical estimate of 
the variance for each test, we calculated the s.d. of residual phenotype mean 
differences in CNV carriers and noncarriers from 5,000 permutations. z-scores 
are calculated as the observed case-control mean difference divided by the 
empirical s.d., with corresponding P values calculated from the standard nor-
mal distribution. Concordance of the initial empirical and z-score P values 
are close to unity for association tests with ≥6 CNVs, whereas z-score P values 
are more conservative among tests with <6 CNVs. Furthermore, the z-score 
method naturally provides an efficient manner to estimate highly significant 
empirical P values that would involve hundreds of millions of permutations 
to achieve. Genome-wide correction for multiple testing was determined as 
described in the Supplementary Note.
Gene set burden enrichment analysis: gene sets. Gene sets with an a priori 
expectation of association to neuropsychiatric disorders were compiled, and 
CNV calls were preprocessed as described in the Supplementary Note.
For each gene set, we fit the following logistic regression model (as imple-
mented by the R function glm of the stats package), where subjects are statisti-
cal sampling units: 
y∼covariates + global+ geneset
Where y is the dicotomic outcome variable (schizophrenia = 1, control = 0); 
‘covariates’ is the set of variables used as covariates also in the genome-wide 
burden and breakpoint-association analysis (sex, genotyping platform, CNV 
metric, and CNV associated principal components); ‘global’ is the measure 
of global genic CNV burden (this covariate accounts for nonspecific asso-
ciation signal that could be merely reflective of an overall difference CNV 
burden between cases and controls. For the results in the main text, we used 
the total gene number (U ) from universal gene set count; we also calculated 
results for total length (TL) and variant number plus variant mean length 
(CNML)); and ‘gene set ‘is the gene set gene count. The gene set burden 
enrichment was assessed by performing a chi-square deviance test (as imple-
mented by the R function anova.glm of the stats package) comparing these two 
regression models: 
y∼covariates + global  
y∼covariates + global+geneset
We reported the following statistics: coefficient beta estimate (Coeff); t-student 
distribution-based coefficient significance P value (as implemented by the 
R function summary.glm of the stats package, abbreviated as Pvalue_ glm); 
deviance test P value (Pvalue_dev); gene set size (i.e., number of genes 
is the gene set, regardless of CNV data); BH-FDR; percentage of schizo-
phrenia and control subjects with at least n genes affected by a CNV of the 
desired type (loss or gain) in the gene set (SZ_g1n, SZ_g2n, … CT_g1n, …). 
By performing simple simulation analyses, we realized that Pvalue_glm can be 
extremely over-conservative in presence of very few gene set counts different 
from 0, whereas Pvalue_dev tends to be slightly under-conservative. Although 
the two P values tended to agree well for gene set analysis, Pvalue_glm is sys-
tematically over-conservative for gene analysis, as smaller counts are typically 
available for single genes.
Gene-association analysis. Subjects were restricted to the ones with at 
least one rare CNV. Only genes with at least a minimum number of subjects 
affected by CNV were tested; this threshold was picked by comparing the 
BH-FDR to the permutation-based FDR and ensuring limited FDR inflation 
(permuted FDR < 1.65 × BH-FDR at BH-FDR threshold = 5%) while maxi-
mizing power. For gains, the threshold was set to 12 counts, and for losses it 
was set to 8 counts.
For each gene, we fit the following logistic regression model (as imple-
mented by the R function glm of the stats package), where subjects are 
statistical sampling units: 
y ∼ covariates + gene
Where y is the dichotomous outcome variable (schizophrenia = 1, control = 0), 
‘covariates’ is the set of variables used as covariates also in the genome-wide 
burden and breakpoint-association analysis (sex, genotyping platform, CNV 
metric, and CNV associated principal components) and ‘gene’ is the binary 
indicator for the subject having or not having a CNV of the desired type 
(loss or gain) mapped to the gene. The gene burden was assessed by per-
forming a chi-square deviance test (as implemented by the R function anova.
glm of the stats package) comparing the regression models y ~ covariates  
and y ~ covariates + gene.
Genome-wide correction for multiple testing was determined as described 
in the Supplementary Note.
Experimental validation of CNV calls by digital droplet PCR. For 6 novel 
candidate loci that were identified in this study, we sought to confirm CNV 
calling accuracy by experimental validation of CNV calls in a subset of study 
samples. Within each association peak, a segment was defined that overlapped 
a majority of calls. Appropriate digital droplet assays were then selected from 
Bio-Rad. A single FAM-labeled probe was designed for DMRT1, ZMYM5, 
ZNF92, MAGEA11 and distal Xq28. Because some deletions of the VPS13B 
gene were nonoverlapping, two different probes were selected for this locus. 
CNV calls (up to a maximum of 17) were selected from the core target region. 
Probe details, CNV calls and validation results can be found in Supplementary 
Table 5. Study samples were then obtained from the respective PGC studies 
and four population control samples were obtained from Coriell Cell reposi-
tories (ND00745, ND01936, ND00689, ND01317) to be used as negative 
controls for ddPCR assays. EcoRI-digested samples (10 ng genomic DNA) 
were analyzed in triplicate by ddPCR using the FAM-labeled CNV probe and 
HEX-labeled reference probe M0005 RPP30-HEX (Supplementary Table 5) 
in the UCSD CFAR Genomics and Sequencing Core. PCR droplets were generated 
using a Bio-Rad QX100 Droplet Generator, then quantitative PCR was performed 
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using the GeneAmp PCR system 9700 (Applied Biosystems) instrument 
according to manufacturer’s protocols (40 cycles at 94 °C for 30 s and 60 °C 
for 1 min). PCR droplets were read and analyzed on Bio-Rad QX100 Droplet 
Reader with QuantaSoft software.
Data availability. Visualization of 16p13.2 is available at http://pgc.tcag.
ca/gb2/gbrowse/pgc_hg18/?name=chr16:8607047..9607046; visualization of 
8q11.23 locus is available at http://pgc.tcag.ca/gb2/gbrowse/pgc_hg18/
?name=chr8:53243575..54243574; gene reviews are available at https://www.
ncbi.nlm.nih.gov/books/NBK349624/. the Genetic Cluster Computer (GCC) 
is available at https://userinfo.surfsara.nl/systems/lisa. The PGC CNV resource 
is available through a custom browser at http://pgc.tcag.ca/gb2/gbrowse/ 
pgc_hg18/, and the rare CNV call set can be obtained from the European 
Genome-Phenome Archive (accession number EGAS00001001960).
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